GGrantIndex
← Leaderboards

Veronika Fedirko

Emory University

$6,615,038
Attributed
$9,961,393
Total exposure
7
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.3M · FY201425
$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,961,393 · 7

By mechanism

R01$9,228,831 · 4
R21$388,572 · 1
R03$343,990 · 2

Top collaborators

Most similar at Emory University

Same institution · by research overlap

Others in their field

Top investigators on “Biological Markers

Research focus

Biological MarkersCancer PatientInflammationBacteriaGut MicrobiomePathway InteractionsRecurrenceMicrobialValidationCancer SurvivorPharmaceutical PreparationsMalignant NeoplasmsDiet16s Ribosomal Rna SequencingDiagnosisCessation Of LifeProspectiveCancer EtiologyColorectal CancerPlayBaseColonPreventionMediating

Grant awards (21)

Gut Microbiome and Cancer Immunotherapy Outcomes in Advanced Renal Cell Carcinoma$876,059
R01 · FY2025 · CA · contact PI
The Role of the Gut Microbiome and Short Chain Fatty Acids in the Regulation of Inflammation and Neuropsychological Symptoms in Patients with Head and Neck Cancer$746,641
R01 · FY2025 · NR
Biological and social determinants of psychosocial sequelae in advanced head and neck cancer survivors receiving immunotherapy$658,403
R01 · FY2025 · CA
The Role of the Gut Microbiome and Short Chain Fatty Acids in the Regulation of Inflammation and Neuropsychological Symptoms in Patients with Head and Neck Cancer$755,208
R01 · FY2024 · NR
Biological and social determinants of psychosocial sequelae in advanced head and neck cancer survivors receiving immunotherapy$664,304
R01 · FY2024 · CA
Gut Microbiome and Cancer Immunotherapy Outcomes in Advanced Renal Cell Carcinoma$139,551
R01 · FY2024 · CA · contact PI
The Role of the Gut Microbiome and Short Chain Fatty Acids in the Regulation of Inflammation and Neuropsychological Symptoms in Patients with Head and Neck Cancer$764,598
R01 · FY2023 · NR
Gut Microbiome and Cancer Immunotherapy Outcomes in Advanced Renal Cell Carcinoma$651,814
R01 · FY2023 · CA · contact PI
The Role of the Gut Microbiome and Short Chain Fatty Acids in the Regulation of Inflammation and Neuropsychological Symptoms in Patients with Head and Neck Cancer$797,582
R01 · FY2022 · NR
Gut Microbiome and Cancer Immunotherapy Outcomes in Advanced Renal Cell Carcinoma$638,550
R01 · FY2022 · CA · contact PI
Gut Microbiome, Antibiotic Use & Colon Cancer Recurrence$446,142
R01 · FY2021 · CA · contact PI
Gut Microbiome, Antibiotic Use & Colon Cancer Recurrence$537,673
R01 · FY2020 · CA · contact PI
Gut Microbiome, Antibiotic Use & Colon Cancer Recurrence$497,046
R01 · FY2019 · CA · contact PI
Gut Microbiome, Antibiotic Use & Colon Cancer Recurrence$505,130
R01 · FY2018 · CA · contact PI
Gut Microbiome, Antibiotic Use & Colon Cancer Recurrence$550,130
R01 · FY2017 · CA · contact PI
Vitamin D3, Calcium and Biomarkers of Gut Barrier Function$172,468
R21 · FY2015 · CA · contact PI
Vitamin D3, Calcium and Inflammation, Immunomodulation and Colonic Permeability$81,695
R03 · FY2015 · CA · contact PI
A Pooled Analysis of 25-hydroxyvitamin D and Colorectal Cancer Survival$79,395
R03 · FY2015 · CA · contact PI
Vitamin D3, Calcium and Biomarkers of Gut Barrier Function$216,104
R21 · FY2014 · CA · contact PI
A Pooled Analysis of 25-hydroxyvitamin D and Colorectal Cancer Survival$93,395
R03 · FY2014 · CA · contact PI
Vitamin D3, Calcium and Inflammation, Immunomodulation and Colonic Permeability$89,505
R03 · FY2014 · CA · contact PI